Breast Cancer Highlights from 2023

Breast Cancer Highlights from 2023

Icon Objectives

Learning Objectives

  1. Articulate appropriate applications and interpretations of significant 2023 research data in breast cancer
  2. Understand how clinicians can integrate evidence-based treatment choices into practice
  3. Review significant data presented this year from key oncology conferences to improve patient management and outcomes
Icon Panelists

Speakers

Dr. Jan-Willem Henning
Dr. Paolo Tarantino

This program has been made possible through unrestricted support from AstraZeneca and Daiichi Sankyo

Studies/trials discussed:

  • KATHERINE study
  • HER2CLIMB-02 trial
  • HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
  • Phase 3 SONIA trial
  • Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
  • Young-PEARL study
  • Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL
  • RIGHT Choice trial
  • NATALEE trial
  • MONARCH 3 trial
  • INAVO120 trial
  • CAPitello-291 trial
  • TROPION-Breast01 trial
  • Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
  • Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial
  • Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2early breast cancer: Primary results from the phase III NATALEE trial
  • Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2advanced breast cancer: final overall survival results of MONARCH 3
  • Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
Tagged